Refractory Wegener's granulomatosis: A model for shorter immunotherapy of autoimmune diseases

Journal of the Royal College of Physicians of London

Volumn 32, Issue 5, 1998, Pages 473-478

  Lockwood, C M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PREDNISOLONE;

ARTICLE; AUTOIMMUNE DISEASE; BIOPSY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ACTIVITY; DISEASE MODEL; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; RELAPSE; REMISSION; SCINTISCANNING; WEGENER GRANULOMATOSIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD4; ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; GLYCOPROTEINS; HUMANS; REMISSION INDUCTION; WEGENER GRANULOMATOSIS;

EID: 0031754770     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Carruthers DM, Watts RA, Symmons DP, Scott DG. Wegener's granulomatosis - increased incidence or increased recognition? Br J Rheumatol 1996;35:142-5.
2. Kallenberg CGM, Brouwer E, Mulder AHL, Stegeman CA, et al. ANCA pathophysiology revisited. Clin Exp Immunol 1995;100:1-3.
3. Cohen Tervaert JW, Huitema MG, Hené RJ, Sluiter WJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990;336:709-11.
4. Jayne DRW, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. QJ Med 1995;88:127-33.
5. Walton EW. Giant cell granuloma of the respiratory tract: Wegener's granulomatosis. Br Med J 1958;2:265-70.
6. Hollander D, Manning RT. The use of alkylating agents in the treatment of Wegener's granulomatosis. Ann Intern Med 1967; 67:393-8.
7. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
8. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's granulomatosis classification criteria cohort. Am J Med 1996;101:129-34.
9. Talar Williams C, Hijazi YM, Walther MM, Lineham WM, et al. Cyclophosphamide induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996;124:477-84.
10. Maskell GF, Lockwood CM, Flower CDR. Computed tomography of the lung in Wegener's granulomatosis. Clin Radiol 1993;48:377-80.
11. Reuter H, Wraight EP, Qasim FJ, Lockwood CM. Management of systemic vasculitis: contribution of scintigraphic imaging to evaluation of disease activity and classification. QJ Med 1995;88:509-16.
12. Muhle C, Reinhold-Keller E, Richter C, Duncker G, et al. MRI of the nasal cavity, the paranasal sinuses and orbits in Wegener's granulomatosis. Eur Radiol 1997;7:566-70.
13. Lockwood CM, Thiru S, Isaacs JD, Hale G, et al. Humanised monoclonal antibody therapy for intractable systemic vasculitis. Lancet 1993;341:1620-2.
14. Hagen EC, de Keizer RJW, Andrassy K, van Boven WPL, et al. Compassionate treatment of Wegener's granulomatosis with rabbit antithymocyte globulin. Clin Nephrol 1995;43:351-9.
15. Lockwood CM, Thiru S, Stewart S, Hale G, et al. Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJ Med 1996;89:903-12.
16. Chen Z, Cobbold S, Metcalf S, Waldmann H. Tolerance in the mouse to major histocompatibility complex mismatched heart allografts and to rat heart xenografts using monoclonal antibodies to CD4 and CD8. Eur J Immunol 1992;22:805-10.
17. Hom JT, Butler LD, Riedl PE, Bendele AM. The progression of the inflammation in established collagen induced arthritis can be altered by treatment with immunological or pharmacological agents which inhibit T cell activities. Eur J Immunol 1988;18:881-8.
18. Adorini L, Sinigaglia F. Pathogenesis and immunotherapy of autoimmune disease. Immunol Today 1997;18:209-11.
19. Steinberg AD. Cyclophosphamide in therapeutic immunology. In: Austen KF, Burakoff SB, Rosen FS, Strom TB (eds). Therapeutic immunology. Cambridge, Mass: Blackwell, 1996:23-43.
20. Wing MG, Moreau T, Greenwood J, Smith RM, et al. Mechanism of first dose cytokine release syndrome by Campath 1H: Involvement of CD16 Fcg-R111 and CD 11a/CD/18 (LFA-1) on NK cells. J Clin Invest 1996;98:2819-26.